We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Pharmaron Acquires Quotient Bioresearch

Rectangle Image
News

Pharmaron Acquires Quotient Bioresearch

Read time:
 

Pharmaron has announced that it acquired Quotient Bioresearch (Quotient). Quotient, a UK-based CRO with more than 200 employees, focuses on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient’s previous acquisition of GE Amersham’s radiosynthesis business.

Integrated with Pharmaron’s broader technology platforms in chemistry, biology, DMPK, pharmacology, safety assessment, chemical and pharmaceutical development, this acquisition strengthens the company’s service portfolio, allowing it to provide more comprehensive and integrated services. The addition of the radiochemistry capabilities creates a global leading chemistry platform with a full spectrum of services. Further, the combined entity will generate greater market access in Asia, Europe and the United States.

“We are very pleased to have Quotient Bioresearch join the Pharmaron team.” said Dr. Boliang Lou, Chairman and Chief Executive Officer of Pharmaron. “This acquisition is part of our long-term strategy to grow our services and broaden our technical and geographic footprint to better serve clients throughout the world. Combining these two companies gives Pharmaron industry-leading custom radiosynthesis capabilities, and further consolidates our leading position in the field of discovery, pre-clinical and clinical DMPK. This move will help accelerate the discovery and development of novel drugs for our customers with Pharmaron’s comprehensive and integrated drug research and development engine.”

Stephen Lewinton, Managing Director of Quotient, said, “Quotient is focused on radiosynthesis and regulatory DMPK, particularly human clinical metabolism while Pharmaron has premier expertise in drug R&D services including discovery and pre-clinical safety and early phase DMPK. We are excited to become part of Pharmaron’s integrated drug research and development platform.”

Teneo Capital served as financial advisor to Pharmaron in the transaction and O’Melveny & Meyers LLP served as Pharmaron’s legal advisor.

Advertisement